Aclaris Therapeutics Inc.

ACRS

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Rock Springs Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management0.0%Feb 14, 2024

SC 13GRA Capital Management7.1%Apr 25, 2022

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 4,453,741Value: $13.4M

# Signal Note: Rock Springs Capital Initiates ACRS Position Rock Springs' $13.4M entry into ACRS signals conviction in the dermatology specialist's pipeline, likely centered on ATI-2138 (JAK inhibitor for alopecia areata) ahead of potential 2024-2025 clinical readouts. The position size (~4.5M shares, ~5% of float) suggests meaningful conviction from a healthcare-focused specialist, though ACRS carries execution risk given prior clinical setbacks and capital requirements. Catalysts to monitor: Phase 2b AA data timing and potential strategic partnerships or financing announcements.

More ACRS Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

MLYS1 fund NBIX1 fund OLMA1 fund MIRM1 fund AMLX1 fund NAMSW1 fund OMDA1 fund REGN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: